Fate Therapeutics, Inc. (NASDAQ: FATE) is a Healthcare company (Biotechnology) with a market capitalization of $119M. The Maz Rating grades it against the other companies in its sector.
Fate Therapeutics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.02, Fate Therapeutics, Inc. trades at 25.1x sales and 1.0x book value. Over the last twelve months it generated about $5M of revenue and a net loss of $120M. It runs a gross margin of -17.8%, an operating margin of -2760.0% and a net margin of -2619.6%. It shows return on equity of -73.9%, return on invested capital of -62.2% and a free cash flow yield of -90.4%. On the balance sheet: a debt-to-equity ratio of 0.56 and a current ratio of 4.41. Over the past 52 weeks the share price ranged from $0.95 to $3.23, with a beta of 2.67.
Fate Therapeutics, Inc. does not currently pay a dividend.
31 Wall Street analyst ratings cover the stock: 16 Buy, 13 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Fate Therapeutics, Inc. (FATE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 52.5% / 30% · Interest income / Revenue 140900000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 52.5% / 33% · Receivables / Mkt Cap (36m) 0.18% / 49% · Interest income / Revenue 140900000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 52.5% / 33.33% · Receivables / Mkt Cap (24m) 0.18% / 33.33% · Interest income / Revenue 140900000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 13.2% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 60.9% / 33.33% · Receivables / Avg Assets (4Q) 0.25% / 33.33% · Interest income / Revenue 140900000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 58.4% / 33.33% · (Cash+Recv) / Total Assets 58.6% / 33.33% · Interest income / Revenue 140900000.0% / 5% | Fail |
No. As of September 2026, Fate Therapeutics, Inc. (FATE) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Fate Therapeutics, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 140900000.0% of each dividend: Fate Therapeutics, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.